TMCnet News
Insomnia Pipeline Highlights 2017-2020 - Research and MarketsResearch and Markets has announced the addition of the "Insomnia Pipeline Highlights - 2017" drug pipelines to their offering. This report, Insomnia Pipeline Highlights - 2017, provides the most up-to-date information on key pipeline products in the global Insomnia market. It covers emerging therapies for Insomnia in active clinical development stages, including early- and late-stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals. Clinical Trial Stages: The report provides Insomnia pipeline products by clinical trial stages, including both early- and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage. Drug Mechanism Classes: The report provides Insomnia pipeline products by their dominant mechanism of action. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds. Company: The report provides Insomnia pipeline products by the company. Short-Term Launch Highlights: Find out which Insomnia pipeline products will be launched in the US and Ex-US till 2020. Summary: - Insomnia phase 3 clinical trial pipeline products - Insomnia phase 2 clinical trial pipeline products - Insomnia phase 1 clinical trial pipeline products - Insomnia preclinical research pipeline products - Insomnia discovery-stage pipeline products - Insomnia pipeline products short-term launch highlights For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/ll8rl8/insomnia_pipeline.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170123005957/en/ |
